In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.19 below Eli Lilly And Company average.

Within Major Pharmaceutical Preparations industry 417 other companies have achieved higher Quick Ratio than Eli Lilly in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2944 to 3295.

Explain Quick Ratio?
How much Cash & cash equivalents LLY�s has?
What are LLY�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LLY Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	22.35 %	3.07 %	-37.11 %	83.93 %	43.87 %
Y / Y Cash & cash equivalent Change	152.4 %	64 %	109.57 %	181.76 %	5.41 %
Quick Ratio MRQ	0.19	0.28	0.41	0.44	0.09
LLY's Total Ranking	# 3295	# 2944	# 434	# 2288	# 3147
Seq. Current Liabilities Change	150.12 %	6.95 %	-20.76 %	-42.28 %	110.72 %
Seq. Cash & cash equivalent Change	69.44 %	-27.33 %	-26.69 %	179.57 %	10.1 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 418
Healthcare Sector	# 824
Overall Market	# 3295

Quick Ratio Statistics
High	Average	Low
2.73	0.62	0.02
(Mar 31 2016)

Financial Statements
Eli Lilly's Current Liabilities	$ 47,741 Millions	Visit LLY's Balance sheet
Eli Lilly's Cash & cash equivalent	$ 8,950 Millions	Visit LLY's Balance sheet
Source of LLY's Sales		Visit LLY's Sales by Geography

Cumulative Eli Lilly's Quick Ratio

LLY's Quick Ratio for the trailling 12 Months

LLY Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	9.21 %	14.16 %	27.3 %	36.87 %	26.73 %
Y / Y Cash & cash equivalent TTM Growth	128.41 %	91.65 %	85.12 %	61.99 %	20.5 %
Quick Ratio TTM	0.29	0.26	0.24	0.19	0.14
Total Ranking TTM	# 4169	# 4098	# 672	# 3316	# 3214
Seq. Current Liabilities TTM Growth	8.86 %	0.58 %	-9.71 %	10.47 %	13.79 %
Seq. Cash & cash equivalent TTM Growth	20.78 %	8.61 %	18.86 %	46.5 %	1.34 %

Quick ratio ranking by company, industry and sector >> Back to LLY Financial Strength Comparisons >> Go to Compare LLY Quick Ratio to its Competitors

On the trailing twelve months basis LLY Cash & cash equivalent more than doubled by 152.4 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Eli Lilly's Quick Ratio to 0.29, Quick Ratio remained below LLY average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 444 other companies have achieved higher Quick Ratio than Eli Lilly. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 4098 to 4169.

Explain Quick Ratio?
How much Cash & cash equivalents LLY�s has?
What are LLY�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 445
Healthcare Sector	# 916
Within the Market	# 4169

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.02	0.53	0.11
(June 30. 2006)		(Jun 30 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Citius Oncology Inc	0.50	$ 16.564 Millions	$ 33.152 Millions
Verrica Pharmaceuticals Inc	0.50	$ 11.198 Millions	$ 22.442 Millions
Aytu Biopharma Inc	0.48	$ 26.308 Millions	$ 54.659 Millions
Jupiter Neurosciences Inc	0.47	$ 1.522 Millions	$ 3.251 Millions
Aeon Biopharma inc	0.47	$ 3.431 Millions	$ 7.342 Millions
Evolus Inc	0.46	$ 45.170 Millions	$ 98.731 Millions
Biomarin Pharmaceutical Inc	0.45	$ 874.005 Millions	$ 1,927.164 Millions
Pds Biotechnology Corp	0.45	$ 5.596 Millions	$ 12.377 Millions
Biofrontera Inc	0.44	$ 4.659 Millions	$ 10.541 Millions
Beyondspring Inc	0.43	$ 10.361 Millions	$ 23.834 Millions
Organon and Co	0.43	$ 1,132.000 Millions	$ 2,616.000 Millions
Gossamer Bio Inc	0.41	$ 57.026 Millions	$ 137.783 Millions
Bausch Health Companies Inc	0.39	$ 1,825.000 Millions	$ 4,687.000 Millions
Johnson and Johnson	0.38	$ 21,094.000 Millions	$ 54,895.000 Millions
Ultragenyx Pharmaceutical Inc	0.36	$ 125.000 Millions	$ 351.000 Millions
Vanda Pharmaceuticals Inc	0.34	$ 56.119 Millions	$ 164.026 Millions
Ainos Inc	0.29	$ 1.423 Millions	$ 4.928 Millions
Elanco Animal Health Incorporated	0.29	$ 530.000 Millions	$ 1,852.000 Millions
Provectus Biopharmaceuticals Inc	0.27	$ 1.157 Millions	$ 4.234 Millions
Vireo Growth Inc.	0.27	$ 104.100 Millions	$ 390.700 Millions
Phibro Animal Health Corporation	0.26	$ 81.994 Millions	$ 316.468 Millions
Merck and Co Inc	0.26	$ 7,141.000 Millions	$ 27,731.000 Millions
Indivior Pharmaceuticals Inc	0.26	$ 222.000 Millions	$ 868.000 Millions
Propanc Biopharma Inc	0.25	$ 0.832 Millions	$ 3.354 Millions
Teva Pharmaceutical Industries Limited	0.23	$ 3,655.000 Millions	$ 15,646.000 Millions
Cytodyn inc	0.22	$ 11.852 Millions	$ 53.727 Millions
Collegium Pharmaceutical Inc	0.22	$ 129.467 Millions	$ 589.861 Millions
International Stem Cell Corporation	0.22	$ 1.089 Millions	$ 4.984 Millions
Earth Science Tech Inc	0.22	$ 0.631 Millions	$ 2.902 Millions
Viatris Inc	0.22	$ 1,368.700 Millions	$ 6,345.800 Millions

Date modified: 2026-09-12T18:39:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.